EU/3/15/1494 - orphan designation for treatment of diffuse large B-cell lymphoma

Humanised anti-CD37 monoclonal antibody conjugated to maytansinoid DM1 (naratuximab emtansine)

Overview

Please note that this product was withdrawn from the Union Register of orphan medicinal products in July 2022 on request of the Sponsor.

On 21 May 2015, orphan designation (EU/3/15/1494) was granted by the European Commission to ImmunoGen Europe Limited, United Kingdom, for humanised anti-CD37 monoclonal antibody conjugated to maytansinoid DM1 for the treatment of diffuse large B-cell lymphoma.

This medicine is now known as naratuximab emtansine.

What is diffuse large B-cell lymphoma?

Diffuse large B-cell lymphoma is a type of blood cancer and the most common form of a group of blood cancers known as non-Hodgkin lymphomas.

Diffuse large B-cell lymphoma affects a type of white blood cell called B lymphocytes, or B cells. In patients with this cancer, the B cells multiply too quickly and live for too long, so there are too many of them in the lymph nodes. The first sign of the disease is usually a lump in the neck, under the arm or in the groin area, which is caused by an enlarged lymph node. Patients with diffuse large B-cell lymphoma may also have fever, tiredness, night sweats or weight loss that have no obvious cause.

Although some people with diffuse large B-cell lymphoma can be cured, it remains a serious and life-threatening disease, particularly when the disease is diagnosed late or has come back after initial treatment.

What is the estimated number of patients affected by the condition?

At the time of designation, diffuse large B-cell lymphoma affected approximately 2.7 in 10,000 people in the European Union (EU). This was equivalent to a total of around 138,000 people*, and is below the ceiling for orphan designation, which is 5 people in 10,000. This is based on the information provided by the sponsor and the knowledge of the Committee for Orphan Medicinal Products (COMP).

---

*Disclaimer: For the purpose of the designation, the number of patients affected by the condition is estimated and assessed on the basis of data from the European Union (EU 28), Norway, Iceland and Liechtenstein. This represents a population of 512,900,000 (Eurostat 2015).

What treatments are available?

At the time of designation, several medicines were authorised for the treatment of diffuse large B-cell lymphoma in the EU. The main treatment was chemotherapy (medicines to treat cancer) usually in combination with other medicines called monoclonal antibodies and sometimes in combination with radiotherapy (treatment with radiation). Autologous haematopoietic (blood) stem-cell transplantation was also used in patients at risk of the disease coming back after treatment. This is a complex procedure where patients receive their own stem cells to help restore the bone marrow.

The sponsor has provided sufficient information to show that this medicine might be of significant benefit for patients with diffuse large B-cell lymphoma because early studies showed that it may improve the outcome of patients with the condition. This assumption will need to be confirmed at the time of marketing authorisation, in order to maintain the orphan status.

How is this medicine expected to work?

This medicine is made up of two active components, which are linked together:

• a monoclonal antibody (a type of protein) that has been designed to recognise and attach to a receptor called CD37, which is present in high amounts on the surface of cancerous B cells.
• maytansinoid DM1, a toxic substance that kills cells when they attempt to divide and grow. It attaches to a protein in cells called 'tubulin', which is important in the formation of the internal 'skeleton' that cells need to assemble when they divide. By attaching to tubulin in cancer cells, maytansinoid DM1 stops the formation of this skeleton, preventing the division and growth of the cancer cells.

The medicine is expected to attach to CD37 on the surface of cancerous B cells and enter the cell. It is expected that the maytansinoid DM1 component will then be released inside the cancer cell, causing it to die.

What is the stage of development of this medicine?

The effects of the medicine have been evaluated in experimental models.

At the time of submission of the application for orphan designation, clinical trials with the medicine in patients with diffuse large B-cell lymphoma were ongoing.

At the time of submission, the medicine was not authorised anywhere in the EU for diffuse large B-cell lymphoma or designated as an orphan medicinal product elsewhere for this condition.

In accordance with Regulation (EC) No 141/2000 of 16 December 1999, the COMP adopted a positive opinion on 16 April 2015 recommending the granting of this designation.

Opinions on orphan medicinal product designations are based on the following three criteria:

• the seriousness of the condition;
• the existence of alternative methods of diagnosis, prevention or treatment;
• either the rarity of the condition (affecting not more than 5 in 10,000 people in the EU) or insufficient returns on investment.

Designated orphan medicinal products are products that are still under investigation and are considered for orphan designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of quality, safety and efficacy is necessary before a product can be granted a marketing authorisation.

Key facts

• Active substance:
  Humanised anti-CD37 monoclonal antibody conjugated to maytansinoid DM1 (naratuximab emtansine)
• Intended use:
  Treatment of diffuse large B-cell lymphoma
• Orphan designation status:
  Withdrawn
• EU designation number:
  EU/3/15/1494
• Date of designation:
  18/07/2022
• Sponsor:

  Voisin Consulting S.A.R.L.; 64 Avenue Pierre Grenier; 92100 Boulogne-Billancourt; France; Tel: [phone]; E-mail : [e-mail]

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.